Literature DB >> 8781611

Renal transplantation exposes patients with previous Kaposi's sarcoma to a high risk of recurrence.

J M Doutrelepont1, L De Pauw, S A Gruber, D L Dunn, W Qunibi, P Kinnaert, P Vereerstraeten, I Penn, D Abramowicz.   

Abstract

It is currently estimated that about 0.5% of patients will develop Kaposi's sarcoma (KS) after kidney transplantation. Tapering of immunosuppression often leads to KS remission, but also results in graft loss in more than 50% of cases. Whether retransplantation is safe in these patients is unknown. We here report on eight patients who developed KS recurrence after kidney transplantation-(A) Patients with previously treated KS: There were 4 patients who had clinical remission of KS (including three posttransplantation) for periods ranging from 5 months up to 19 years before transplantation. All 4 developed KS recurrence within months after transplantation. In 3 patients, KS regressed only when all immunosuppression was discontinued, at the price of allograft removal. Partial remission occurred in the fourth patient following reduction of immunosuppression and gancyclovir administration; (B) Patients with recurrent KS during a single transplant: 4 patients developed KS after transplantation that regressed following reduction of immunosuppressive therapy. Increased immunosuppression, in the form of steroid pulses in 3 patients was associated with recurrence of KS. Subsequent reduction of immunosuppression caused regression of KS in all 4 patients, but 2 recipients lost their allografts. These data emphasize the high risk of recurrence of KS after renal transplantation. If physicians decide to transplant patients with a history of KS, they should inform the future recipient of the possibility of KS recurrence.

Entities:  

Mesh:

Year:  1996        PMID: 8781611     DOI: 10.1097/00007890-199608270-00007

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  6 in total

1.  Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy.

Authors:  D H Kedes; D Ganem
Journal:  J Clin Invest       Date:  1997-05-01       Impact factor: 14.808

2.  Sirolimus for visceral and cutaneous Kaposi's sarcoma in a renal-transplant recipient.

Authors:  Osama Gheith; Adel Bakr; Ehab Wafa; Ashraf Fouda; Amgad El Agroudy; Ayman Refaie; Ahmed Donia; Alaa Sabry; Mohamed Sobh; Ahmed Shokeir; Mohamed Ghoneim
Journal:  Clin Exp Nephrol       Date:  2007-09-28       Impact factor: 2.801

Review 3.  Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review.

Authors:  Alex Gutierrez-Dalmau; Josep M Campistol
Journal:  Drugs       Date:  2007       Impact factor: 9.546

4.  National Scientific Medical Meeting. 26-27 March 1999. Abstracts.

Authors: 
Journal:  Ir J Med Sci       Date:  1999 Apr-Jun       Impact factor: 2.089

5.  Rapamycin-induced remission of Kaposi's sarcoma is not associated with expansion of cytotoxic T-lymphocyte subsets.

Authors:  Stephen B Walsh; Shaun A Summers; Peter L Amlot; Michael T Sheaff; Guy H Neild
Journal:  NDT Plus       Date:  2008-06-16

Review 6.  HHV-8 Seroprevalence and Genotype Distribution in Africa, 1998⁻2017: A Systematic Review.

Authors:  Elizabeth M Etta; Doyinmola P Alayande; Lufuno G Mavhandu-Ramarumo; George Gachara; Pascal O Bessong
Journal:  Viruses       Date:  2018-08-27       Impact factor: 5.048

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.